The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis. “Its mechanism of action is fairly unique in dermatology,” Bissonnette ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter at the American Academy of Dermatology Annual Meeting.

Acknowledged for her extensive contributions to dermatology, Elewski is respected internationally as a leader in dermatological diseases, particularly plaque psoriasis and onychomycosis, which has led ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...